Prevalence

Pharming Group reports fourth quarter and full year 2023 financial results

Retrieved on: 
Thursday, March 14, 2024
Patient, Health care, Epidemiology, Executive Committee, Laboratory, Microsoft Access, Lymphocyte, Clinical trial, European Commission, APDS, MHLW, AEG, Welfare, Ageing, Committee, EMA, Trial of the century, PID, CTLA4, Safety, Pharmacokinetics, Ministry, CHMP, ODD, U.S. FDA, Prevalence, PTEN, Disease, HAE, Immunodeficiency, VUS, Literature, PIK3R1, PMDA, FDA, DSM-IV codes, Diagnosis, Civil service commission, IRP, Haploinsufficiency, Genetic testing, MAA, Autoimmunity, World Games, Iberian languages, Marketing, MHRA, Euronext Amsterdam, PIK3CD, Physician, Pharmaceutical industry

The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.

Key Points: 
  • The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
  • Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
  • Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.

Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Checkmate, Prevalence, Patient, World Games, SWOT, Biomarker, Research, NCCN, Cancer, EMA, Contract research organization, National Comprehensive Cancer Network, Protein, Medicine, Clinical trial, Drug development, Therapy, Precision, FDA, Pharmaceutical industry

Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.

Key Points: 
  • Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.
  • The Precision Oncology - Global Clinical Trial Landscape whitepaper is designed for researchers, clinicians, pharmaceutical, biopharma and biotech firms.
  • It presents a thorough analysis of healthcare, technology, macroeconomic, regulatory trends, SWOT analysis, funding, and innovative research developments in precision oncology.
  • The report provides a detailed review of the current precision oncology landscape including standout trials, important trends around FDA approvals, funding initiatives, and ongoing insights impacting research and development.

Springbig Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
PIN, Software as a service, Prevalence, VIP, Table, Adjustment, BOCA, GAAP, Marketing, Total, SBIG, Bookkeeping

BOCA RATON, Fla., March 12, 2024 (GLOBE NEWSWIRE) -- SpringBig Holdings, Inc. (“Springbig” or the “Company”) (OTCQX: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • BOCA RATON, Fla., March 12, 2024 (GLOBE NEWSWIRE) -- SpringBig Holdings, Inc. (“Springbig” or the “Company”) (OTCQX: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs, today announced its financial results for the fourth quarter and full year ended December 31, 2023.
  • Full Year 2023 Financial Highlights:
    Revenue was $28.1 million, an increase of 5% from the prior year.
  • For the first quarter of 2024, Springbig currently expects:
    Revenue in the range of $6.4 - $6.7 million.
  • Adjusted EBITDA is a non-GAAP financial measure provided in this “Financial Outlook” section on a forward-looking basis.

EverythingALS Launches the Vision 2030 AI Hub: Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research

Retrieved on: 
Tuesday, March 12, 2024
Research, Neurology, Harvard Medical School, Synthetic media, Machine learning, Government, Regeneration, Prevalence, Massachusetts General Hospital, Science, Environment, MIT, Data science, SAN, Knowledge, Biomarker, History, Hope, Doctor of Philosophy, LLM, Vision 2030, Hub, Ecosystem, Drug development, Navar, Frontotemporal dementia, Artificial intelligence, Generative, Mass, Medicine, Medical device

The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.

Key Points: 
  • The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.
  • The Vision 2030 AI Hub epitomizes this momentous convergence—where the cumulative advances in ALS research and technology coalesce, heralding a new epoch of hope and discovery.
  • The Vision 2030 AI Hub motivates giving and fundraising, showcasing an innovative operating model that emphasizes urgency in tackling ALS and other disorders.
  • For more information about EverythingALS, Vision 2030, and the AI Hub visit http://www.v2030.org or email us at [email protected] .

The State of Secrets Sprawl 2024

Retrieved on: 
Tuesday, March 12, 2024
Cloud, Synthetic media, DMCA, Google Cloud, Education, Organization, OpenAI, Prevalence, Incidence, Risk, Research, Python Package Index, Toyota, AWS, Generative, GitHub, Cloudflare, API, Privacy, Secrecy, Finance, Mobile phone

PARIS and BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- GitGuardian, the world leader in automated secrets detection, launched today its 2024 edition of the State of Secrets Sprawl report. The study —the most comprehensive research on exposed secrets in public GitHub— reveals that 12.8M new secrets occurrences were leaked publicly on GitHub in 2023, +28% compared to 2022. Remarkably, the incidence of publicly exposed secrets has quadrupled since the company started reporting in 2021.

Key Points: 
  • State of Secrets Sprawl Report Reveals 12.8M New Secrets Occurrences Detected in 2023; Up 28% From 2022
    The study reveals a concerning trend: more than 90% of the secrets remain valid 5 days after being leaked
    PARIS and BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- GitGuardian , the world leader in automated secrets detection, launched today its 2024 edition of the State of Secrets Sprawl report.
  • In 2023 alone, over 1 million valid occurrences of Google API secrets, 250,000 Google Cloud secrets, and 140,000 AWS secrets were detected.
  • Download the State of Secrets Sprawl 2024 report here.
  • Lastly, the report provides a set of valuable recommendations for organizations committed to tackling secrets sprawl.

Study Evaluates Prevalence of Four Recommended Practices for Suicide Prevention Following Hospital Discharge

Retrieved on: 
Tuesday, March 12, 2024
Elsevier, Prevalence, Joint, Joint Commission, Health, The Pew Charitable Trusts, Risk, Nursing care plan, Patient, Hospital, NPSG, Death, ABPP, LMSW, Quality, MPH, Doctor of Psychology, Safety, Suicide, Pew, Patient safety, Nursing

A new study , funded by Pew Charitable Trusts, in The Joint Commission Journal on Quality and Patient Safety (JQPS), evaluated the prevalence of four suicide prevention activities following hospital discharge among Joint Commission-accredited hospitals:

Key Points: 
  • A new study , funded by Pew Charitable Trusts, in The Joint Commission Journal on Quality and Patient Safety (JQPS), evaluated the prevalence of four suicide prevention activities following hospital discharge among Joint Commission-accredited hospitals:
    While these specific suicide prevention activities are not explicitly required by The Joint Commission’s National Patient Safety Goal (NPSG), they are recommended by many suicide prevention experts.
  • By understanding the adoption of recommended practices for suicide prevention, hospitals can help improve care for people at risk and save lives.”
    Researchers calculated the percentage of hospitals reporting the implementation of these recommended discharge practices.
  • While hospitals typically implemented common (and low resource) discharge practices such as providing a list of crisis resources and making referrals, many of the recommended and more robust suicide prevention practices had not yet been widely implemented.
  • Very few hospitals (4%) met full criteria for implementing all four recommended suicide prevention activities at time of discharge.

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Retrieved on: 
Saturday, April 6, 2024
Health Technology, Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Practice Management, Apps, Applications, Managed Care, General Health, Hospitals, Artificial Intelligence, Other Technology, Software, Networks, Health, Mobile, Wireless, Intelligence, Workspace, Medicine, HLA, Research, Genotype, Prevalence, AI

Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform.
  • Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation.
  • This new interface provides researchers a frictionless workflow for surfacing critical insights to power scientific discovery and development.
  • Lens is already trusted by nearly 100 institutions, including healthcare systems and biopharma companies, to power research that improves patient outcomes.

Global Boutique Gym Studios Market Report 2024, Featuring Key Players F45 Training, Xponential Fitness, Equinox Group, Les Mills, CorePower Yoga, CrossFit, Solidcore, BoxUnion, SLT and Physique 57 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Women, Consumer, Health, Fitness & Nutrition, Men, Overweight, Conditional sentence, Obesity, High, Longevity, Motivation, Growth, Urbanization, Prevalence, Woman, Communication, Digital, Diabetes, Ageing, Yoga, Social media, Mental health, Stroke, Cancer, Millennials, Computer, Age, High-intensity interval training, HIIT, Posture, Revenue stream, Air pollution, Gender, Healthline, Retail

The global boutique gym studios market was valued at US$34.35 billion in 2023 and is expected to reach US$54.81 billion by 2029.

Key Points: 
  • The global boutique gym studios market was valued at US$34.35 billion in 2023 and is expected to reach US$54.81 billion by 2029.
  • The global boutique gym studio market has witnessed significant popularity in recent years with consumers increasingly turning to boutique gym studios for a more personalized and unique workout experience.
  • With millennials comprising a significant portion of gym membership holders, their increasing population directly impacts the growth of the boutique gym studios market.
  • The key players in the global boutique gym studios market are:

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.

United States Clinical Oncology Next Generation Sequencing Market Research Report 2023-2028: Data Analysis and Interpretation Tools to Streamline Processes and Growth in Genomic Medicine - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Genetics, Health, Oncology, Lifestyle, Theft, Genomics, Growth, Prevalence, Disease, Data analysis, Incidence, Risk, Patient, NGS, Health care, Cancer, Risk assessment, Laboratory, Quality of life, Medicine, Confidentiality, Identity theft, HIPAA, Interpretation, Treatment, Investment, Privacy, Medical imaging

United States Clinical Oncology Next Generation Sequencing Market is anticipated to project robust growth in the forecast period.

Key Points: 
  • United States Clinical Oncology Next Generation Sequencing Market is anticipated to project robust growth in the forecast period.
  • The United States Clinical Oncology Next Generation Sequencing (NGS) market is a dynamic and rapidly evolving sector within the broader healthcare and life sciences industry.
  • The United States is a global leader in clinical oncology NGS, with numerous academic institutions, research centers, and biotechnology companies actively engaged in cutting-edge research and development.
  • Additionally, data analysis tools that adhere to standardized formats promote collaboration, knowledge exchange, and innovation in clinical oncology.